NO20092616L - Antifolatmiddelkombinasjoner i behandling av kreft - Google Patents

Antifolatmiddelkombinasjoner i behandling av kreft

Info

Publication number
NO20092616L
NO20092616L NO20092616A NO20092616A NO20092616L NO 20092616 L NO20092616 L NO 20092616L NO 20092616 A NO20092616 A NO 20092616A NO 20092616 A NO20092616 A NO 20092616A NO 20092616 L NO20092616 L NO 20092616L
Authority
NO
Norway
Prior art keywords
enhance
treatment
cancer
certain
agent combinations
Prior art date
Application number
NO20092616A
Other languages
English (en)
Other versions
NO344316B1 (no
Inventor
Charles P Theuer
Bonne Jean Adams
Original Assignee
Tracon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39775383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092616(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tracon Pharmaceuticals Inc filed Critical Tracon Pharmaceuticals Inc
Publication of NO20092616L publication Critical patent/NO20092616L/no
Publication of NO344316B1 publication Critical patent/NO344316B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Preparater og metoder anvendelige ved behandling av visse kreftformer. Metoden omfatter administrering til en pasient som mottar et antifolat anticancer middel metoksyamin administrert i en mengde tilstrekkelig til å forbedre eller øke effekten av antifolat anticancermidlet. Denne søknaden er delvis basert på erkjennelsen av at visse molekyler som målsøker abasiske lesjoner eller AP seter i DNA forbedrer, forøker eller forsterker den kjemoterapeutiske effektivitet av visse anticancer midler. 1
NO20092616A 2006-12-29 2009-07-10 Anvendelse av antifolatmiddelkombinasjoner i behandling av kreft NO344316B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87783606P 2006-12-29 2006-12-29
US88326607P 2007-01-03 2007-01-03
US88395907P 2007-01-08 2007-01-08
PCT/US2007/088666 WO2008083107A2 (en) 2006-12-29 2007-12-21 Antifolate agent combinations in the treatment of cancer

Publications (2)

Publication Number Publication Date
NO20092616L true NO20092616L (no) 2009-09-22
NO344316B1 NO344316B1 (no) 2019-11-04

Family

ID=39775383

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092616A NO344316B1 (no) 2006-12-29 2009-07-10 Anvendelse av antifolatmiddelkombinasjoner i behandling av kreft

Country Status (15)

Country Link
US (1) US8017618B2 (no)
EP (1) EP2173333B1 (no)
JP (1) JP5249239B2 (no)
KR (1) KR101195366B1 (no)
CN (2) CN104958299A (no)
AU (1) AU2007339918B2 (no)
BR (1) BRPI0722053A2 (no)
CA (1) CA2674075C (no)
ES (1) ES2688938T3 (no)
GB (1) GB2453011B (no)
HK (1) HK1215683A1 (no)
IL (1) IL199609A0 (no)
MX (1) MX2009007144A (no)
NO (1) NO344316B1 (no)
WO (1) WO2008083107A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2602475T3 (es) * 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
US10725042B2 (en) * 2012-05-22 2020-07-28 Case Western Reserve University Methods of diagnosing and treating cancer
JP2014001204A (ja) * 2012-05-23 2014-01-09 Kumamoto Univ 腫瘍細胞選択的抗がん剤
CN111481551B (zh) * 2013-04-09 2023-06-09 伊利诺伊大学董事会 肿瘤选择性联合疗法
US20160051679A1 (en) * 2013-04-12 2016-02-25 Actavis Group Ptc Ehf. Pemetrexed Formulation
WO2017020048A1 (en) * 2015-07-30 2017-02-02 Expression Pathology, Inc. QUANTIFYING FR-α AND GART PROTEINS FOR OPTIMAL CANCER THERAPY
EA201990473A1 (ru) 2016-08-12 2019-07-31 Эл.И.Эй.Эф. ХОЛДИНГС ГРУП ЭлЭлСи Полиглутамированные антифолаты и их применение
WO2018147437A1 (ja) * 2017-02-10 2018-08-16 学校法人神戸学院 低分子医薬化合物の経粘膜吸収促進剤
KR102040034B1 (ko) * 2017-12-13 2019-11-05 주식회사 아이큐어비앤피 페메트렉시드를 포함하는 경구용 약학 조성물 및 이의 제조방법
CA3090506A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
EP3749311A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC PEMETREXED POLYGLUTAMATE GAMMA COMPOSITIONS AND THEIR USES
WO2019157123A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
EP3749316A4 (en) 2018-02-07 2021-10-27 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED PRALATREXATE AND USES THEREOF
EP3749312A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
CN111954529A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化氨甲蝶呤及其用途
US11779584B2 (en) 2018-02-07 2023-10-10 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
WO2019157148A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
US12048766B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
EP3752156A4 (en) 2018-02-14 2021-10-27 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMIZED PRALATREXATE AND USES THEREOF
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
CN111936145A (zh) 2018-02-14 2020-11-13 L.E.A.F.控股集团公司 γ聚谷氨酸化氨甲蝶呤及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406917B1 (en) 1996-06-11 2002-06-18 Advanced Research And Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
EP0923738A1 (en) 1996-06-11 1999-06-23 Advanced Research & Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2003066889A2 (en) * 2002-02-07 2003-08-14 Axys Pharmaceuticals, Inc. Assay for acytyltransferase or deacetylase activity
GB2385523B (en) * 2002-02-25 2004-01-07 Ronan Anthony Byrne Descent apparatus
US7785578B2 (en) 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
GB0226370D0 (en) * 2002-11-12 2002-12-18 Novartis Ag Organic compounds
AU2004274013A1 (en) 2003-09-17 2005-03-31 Icos Corporation Use of Chk1 inhibitors to control cell proliferation
TWI338000B (en) 2003-12-01 2011-03-01 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
US20060089590A1 (en) 2004-10-27 2006-04-27 John Higuchi Methods and devices for sustained in-vivo release of an active agent
WO2007038687A2 (en) 2005-09-27 2007-04-05 Aciont, Inc. Ocular administration of immunosuppressive agents
WO2007041593A2 (en) 2005-10-03 2007-04-12 Combinatorx, Incorporated Anti-scarring drug combinations and use thereof
CN100500215C (zh) * 2006-01-23 2009-06-17 济南帅华医药科技有限公司 含氨甲喋呤及其增效剂的缓释注射剂

Also Published As

Publication number Publication date
HK1215683A1 (zh) 2016-09-09
AU2007339918B2 (en) 2011-06-02
EP2173333A2 (en) 2010-04-14
GB2453011B (en) 2010-06-23
EP2173333B1 (en) 2018-06-27
GB2453011A (en) 2009-03-25
JP5249239B2 (ja) 2013-07-31
KR101195366B1 (ko) 2012-11-21
BRPI0722053A2 (pt) 2018-04-17
US20080234298A1 (en) 2008-09-25
CA2674075C (en) 2012-10-30
JP2010538967A (ja) 2010-12-16
WO2008083107A2 (en) 2008-07-10
KR20090110843A (ko) 2009-10-22
AU2007339918A1 (en) 2008-07-10
ES2688938T3 (es) 2018-11-07
CA2674075A1 (en) 2008-07-10
CN104958299A (zh) 2015-10-07
NO344316B1 (no) 2019-11-04
IL199609A0 (en) 2010-05-17
US8017618B2 (en) 2011-09-13
MX2009007144A (es) 2009-12-18
CN102014887A (zh) 2011-04-13
GB0812013D0 (en) 2008-08-06
WO2008083107A3 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
MX2009007144A (es) Combinaciones de agente antifolato en el tratamiento de cancer.
WO2004065423A3 (de) Erkennungsmoleküle zur behandlung und detektion von tumoren
LUC00011I1 (no)
PL1819227T3 (pl) Preparat farmaceutyczny decytabiny
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
WO2004087153A3 (en) Use of organic compounds for immunopotentiation
ATE395905T1 (de) Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
WO2008022345A3 (en) Compositions and methods for inhibiting cytochrome p450
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
WO2008131163A8 (en) Enzymatic anticancer therapy
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2008024844A3 (en) Anticancer combination therapies
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2009098464A3 (en) Use of g-rich oligonucleotides for treating neoplastic diseases
WO2008078109A3 (en) Medicament
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
UA96614C2 (ru) Комбинации антифолатного агента в лечении рака
SE0401066D0 (sv) Chemical Derivatives
MD3222G2 (ro) Metodă de diagnostic al cancerului endometrial
WO2006020557A3 (en) Methods of using or identifying agents that inhibit cancer growth

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TRACON PHARMACEUTICALS, US